Corvus Pharma reduces CEO salary from $300K to $34,840; grants 800K options

Corvus Pharmaceuticals, Inc.

CEO base salary cut to $34,840/year effective March 31, 2023, from $300,000.
Option to purchase 800,000 shares granted, vesting monthly over 36 months.
Compensation Committee approved the changes on March 29, 2023.

item 5.02

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-002089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.